FLT3 and acute myeloid leukemia: In conclusion, our study showed there was a trend to a nonsignificantly higher ORR in patients treated with type 2 FLT3 inhibitors as monotherapy in the treatment of R/R AML, which is broadly an effect of a large sample size rather.